Ethnic and socio-cultural specificities in Tunisia have no impact on the prevalence of anti-Saccharomyces cerevisiae antibodies in Crohn's disease patients, their relatives or associated clinical factors

References

• Basu D, Lopez I, Kulkarni A, et al. Impact of race and ethnicity on inflammatory bowel disease. Am J Gastroenterol 2005; 100: 2254–61
   PubMed Web of Science ®Google Scholar
• Mehdi A, Baccouche A. Epidemiologie des maladies inflammatoires cryptogenetiques de l intestin dans le centre est de la Tunisie. Maghreb Med 1997; 314: 47–52
   Google Scholar
• Loftus EV, Jr, Schoenfeld P, Sandborn WJ. The epidemiology and natural history of Crohn's disease in population-based patient cohorts from North America: a systematic review. Aliment Pharmacol Ther 2002; 16: 51–60
   PubMed Web of Science ®Google Scholar
• Binder V. Epidemiology of IBD during the twentieth century: an integrated view. Best Pract Res Clin Gastroenterol 2004; 18: 463–79
   PubMed Web of Science ®Google Scholar
• Sendid B, Colombel JF, Jacquinot PM, et al. Specific antibody response to oligomannosidic epitopes in Crohn's disease. Clin Diagn Lab Immunol 1996; 3: 219–26
   PubMedGoogle Scholar
• Sandborn WJ, Loftus EV, Jr, Colombel JF, et al. Evaluation of serologic disease markers in a population-based cohort of patients with ulcerative colitis and Crohn's disease. Inflamm Bowel Dis 2001; 7: 192–201
   PubMed Web of Science ®Google Scholar
• Barta Z, Csipo I, Szabo GG, et al. Seroreactivity against Saccharomyces cerevisiae in patients with Crohn's disease and celiac disease. World J Gastroenterol 2003; 9: 2308–12
   PubMed Web of Science ®Google Scholar
• Vasiliauskas EA, Kam LY, Karp LC, et al. Marker antibody expression stratifies Crohn's disease into immunologically homogeneous subgroups with distinct clinical characteristics. Gut 2000; 47: 487–96
   PubMed Web of Science ®Google Scholar
• Klebl FH, Bataille F, Bertea CR, et al. Association of perinuclear antineutrophil cytoplasmic antibodies and anti-Saccharomyces cerevisiae antibodies with Vienna classification subtypes of Crohn's disease. Inflamm Bowel Dis 2003; 9: 302–7
   PubMed Web of Science ®Google Scholar
• Peeters M, Joossens S, Vermeire S, et al. Diagnostic value of anti-Saccharomyces cerevisiae and antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease. Am J Gastroenterol 2001; 96: 730–4
   PubMed Web of Science ®Google Scholar
• Mow WS, Vasiliauskas EA, Lin YC, et al. Association of antibody responses to microbial antigens and complications of small bowel Crohn's disease. Gastroenterology 2004; 126: 414–24
   PubMed Web of Science ®Google Scholar
• Sendid B, Quinton JF, Charrier G, et al. Anti-Saccharomyces cerevisiae mannan antibodies in familial Crohn's disease. Am J Gastroenterol 1998; 93: 1306–10
   PubMed Web of Science ®Google Scholar
• Seibold F, Stich O, Hufnagl R, et al. Anti-Saccharomyces cerevisiae antibodies in inflammatory bowel disease: a family study. Scand J Gastroenterol 2001; 36: 196–201
   PubMed Web of Science ®Google Scholar
• Halfvarson J, Standaert-Vitse A, Jarnerot G, et al. Anti-Saccharomyces cerevisiae antibodies in twins with inflammatory bowel disease. Gut 2005; 54: 1237–43
   PubMed Web of Science ®Google Scholar
• Zouiten-Mekki L, Zaouali H, Boubaker J, et al. CARD15/NOD2 in a Tunisian population with Crohn's disease. Dig Dis Sci 2005; 50: 130–5
   PubMed Web of Science ®Google Scholar
• Quinton JF, Sendid B, Reumaux D, et al. Anti-Saccharomyces cerevisiae mannan antibodies combined with antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease: prevalence and diagnostic role. Gut 1998; 42: 788–91
   PubMed Web of Science ®Google Scholar
• Main J, McKenzie H, Yeaman GR, et al. Antibody to Saccharomyces cerevisiae (bakers’ yeast) in Crohn's disease. Br Med J 1988; 297: 1105–6
   PubMed Web of Science ®Google Scholar
• Poulain D, Sendid B, Fajardy I, et al. Mother to child transmission of anti-S. cerevisiae mannan antibodies (ASCA) in non-IBD families. Gut 2000; 47: 870–1
   PubMed Web of Science ®Google Scholar
• Klebl FH, Bataille F, Hofstadter F, et al. Optimising the diagnostic value of anti-Saccharomyces cerevisiae-antibodies (ASCA) in Crohn's disease. Int J Colorectal Dis 2004; 19: 319–24
   PubMed Web of Science ®Google Scholar
• Lindberg E, Magnusson KE, Tysk C, et al. Antibody (IgG, IgA, and IgM) to baker's yeast (Saccharomyces cerevisiae), yeast mannan, gliadin, ovalbumin and betalactoglobulin in monozygotic twins with inflammatory bowel disease. Gut 1992; 33: 909–13
   PubMed Web of Science ®Google Scholar
• McKenzie H, Parratt D, Main J, et al. Antigenic heterogeneity of strains of Saccharomyces cerevisiae and Candida albicans recognised by serum antibodies from patients with Crohn's disease. FEMS Microbiol Immunol 1992; 4: 219–24
   PubMedGoogle Scholar
• Vandewalle P, Standaert A, Seddik M, , et al A new ASCA test based on synthetic oligomannosidic epitopes (Σ ASCA) complements ASCA detection. Gastroenterology 2004;126( A113 (oral presentation)).
   Google Scholar
• Chevalier R, Esnault J, Vandewalle P, et al. Synthetic yeast oligomannosides as biological probes: α-D-Man(1- > 3) α-D-Man (1- > 2) α-D-Man as Crohn's disease marker. Tetrahedron 2005; 61: 7669–77
   Web of Science ®Google Scholar
• Annese V, Andreoli A, Andriulli A, et al. Familial expression of anti-Saccharomyces cerevisiae Mannan antibodies in Crohn's disease and ulcerative colitis: a GISC study. Am J Gastroenterol 2001; 96: 2407–12
   PubMed Web of Science ®Google Scholar
• Ruemmele FM, Targan SR, Levy G, et al. Diagnostic accuracy of serological assays in pediatric inflammatory bowel disease. Gastroenterology 1998; 115: 822–9
   PubMed Web of Science ®Google Scholar
• Arnott ID, Landers CJ, Nimmo EJ, et al. Sero-reactivity to microbial components in Crohn's disease is associated with disease severity and progression, but not NOD2/CARD15 genotype. Am J Gastroenterol 2004; 99: 2376–84
   PubMed Web of Science ®Google Scholar
• Walker LJ, Aldhous MC, Drummond HE, et al. Anti-Saccharomyces cerevisiae antibodies (ASCA) in Crohn's disease are associated with disease severity but not NOD2/CARD15 mutations. Clin Exp Immunol 2004; 135: 490–6
   PubMed Web of Science ®Google Scholar
• Cruyssen BV, Peeters H, Hoffman IE, et al. CARD15 polymorphisms are associated with anti-Saccharomyces cerevisiae antibodies in caucasian Crohn's disease patients. Clin Exp Immunol 2005; 140: 354–9
   PubMed Web of Science ®Google Scholar
• Lawrance IC, Murray K, Hall A, et al. A prospective comparative study of ASCA and pANCA in Chinese and Caucasian IBD patients. Am J Gastroenterol 2004; 99: 2186–94
   PubMed Web of Science ®Google Scholar
• Hisabe T, Matsui T, Sakurai T, et al. Anti-Saccharomyces cerevisiae antibodies in Japanese patients with inflammatory bowel disease: diagnostic accuracy and clinical value. J Gastroenterol 2003; 38: 121–6
   PubMed Web of Science ®Google Scholar
• Forcione DG, Rosen MJ, Kisiel JB, et al. Anti-Saccharomyces cerevisiae antibody (ASCA) positivity is associated with increased risk for early surgery in Crohn's disease. Gut 2004; 53: 1117–22
   PubMed Web of Science ®Google Scholar